A long diagnostic delay in patients with Hereditary Haemorrhagic Telangiectasia: a questionnaire-based retrospective study

Paola Pierucci, Gennaro M Lenato, Patrizia Suppressa, Patrizia Lastella, Vincenzo Triggiani, Raffaella Valerio, Mario Comelli, Daniela Salvante, Alessandro Stella, Nicoletta Resta, Giancarlo Logroscino, Francesco Resta, Carlo Sabbà, Paola Pierucci, Gennaro M Lenato, Patrizia Suppressa, Patrizia Lastella, Vincenzo Triggiani, Raffaella Valerio, Mario Comelli, Daniela Salvante, Alessandro Stella, Nicoletta Resta, Giancarlo Logroscino, Francesco Resta, Carlo Sabbà

Abstract

Background: The difficulty in establishing a timely correct diagnosis is a relevant matter of concern for several rare diseases. Many rare-disease-affected patients suffer from considerable diagnostic delay, mainly due to their poor knowledge among healthcare professionals, insufficient disease awareness among patients' families, and lack of promptly available diagnostic tools. Hereditary Haemorrhagic Telangiectasia (HHT) is an autosomal-dominantly inherited vascular dysplasia, affecting 1:5,000-10,000 patients. HHT is characterized by high variability of clinical manifestations, which show remarkable overlapping with several common diseases.

Aim: To perform a detailed analysis concerning the diagnostic time lag occurring in patients with HHT, defined as the time period spanning from the first clinical manifestation to the attainment of a definite, correct diagnosis.

Methods: A questionnaire was administered to the HHT patients previously recruited from 2000 and 2009. Clinical onset, first referral to a physician for disease manifestations, and first correct diagnosis of definite HHT were collected. Eventual misdiagnosis at first referral and serious complications occurring throughout the time elapsing between disease onset and definite diagnosis were also addressed.

Results: In the 233 respondents, the clinical onset of disease occurred at an age of 14.1 yrs, while the age of first referral and the age of first definite diagnosis of HHT were 29.2 yrs and 40.1 yrs, respectively. Only 88/233 patients received a correct diagnosis at first counseling. Thus, the diagnostic time lag, represented by the time elapsing from disease onset and first definite diagnosis of HHT, proved to be 25.7 yrs. Twenty-two patients suffered from severe complications during this time interval. The diagnostic delay was significantly longer (p < 0.001) in index patients (first patients who attained definite HHT diagnosis in a given family) than in non-index patients (relative of index patients). The diagnostic time lag was also significantly associated with education grade (p < 0.001).

Conclusions: Our data report for the first time a systematic inquiry of diagnostic delay in HHT showing that patients receive a definite diagnosis only after nearly three decades from disease onset. Concerted efforts are still to be made to increase awareness of this disease among both families and physicians.

Figures

Figure 1
Figure 1
Timing steps of diagnosis according to Index/Non-Index Status. RTL = Referral Time Lag; DTL = Diagnosis Time Lag.
Figure 2
Figure 2
Referral Time Lag (RTL) and Diagnosis Time Lag (DTL) according to Index/Non-Index Status and Grade of Education. For each subgroup, the mean value of age of onset, age of 1st referral, and age of 1st definite HHT diagnosis are indicated. In X-axis the time before clinical onset is shown by a white dashed bar. The time comprised between clinical onset and attainment of definite diagnosis of HHT (corresponding to DTL) is shown by a grey full bar. For each subgroup, the mean age of first referral to a physician is labeled by a black vertical rod.
Figure 3
Figure 3
(Panel A: Index patients; Panel B: Non-index patients). Twenty-two patients suffered from severe complications before attainment of HHT definite diagnosis. Each horizontal bar represents one given patient - identified by a number on Y-axis - who suffered from AVM-related complications over the time of Diagnosis Time Lag (DTL). In X-axis the time before clinical onset is shown by a white dashed bar. The time comprised between clinical onset and attainment of definite diagnosis of HHT (corresponding to DTL) is shown by a grey full bar. For each patient, the first referral to a physician is labeled by a black vertical rod. Star-shaped markers indicate complication events: BA = Brain Abscess; BS = Brain Stroke; TIA = Transient Ischemic Attack; ICH = Intracranial Haemorrhage; PRH = Pulmonary Haemorrhage; GRH = Haemorrhage from Large Gastrointestinal Colonic AVM; SZ = Seizures; HOF = High-Output Heart Failure; LINS = Liver Insufficiency; OLTx = Orthotopic Liver Transplantation.
Figure 4
Figure 4
Diagnostic Time Lag (DTL) in several Rare Diseases. In Y-axis, the DTL is shown for the following rare diseases: FMF = Familial Mediterranean Fever [9]; A1-ATD = Alfa-1 Antitrypsin Deficiency [10]; RP = Relapsing Polychondritis [11]; ALS = Amyotrophic Lateral Sclerosis [9]; MarS = Marfan Syndrome [12]; PWS = Prader-Willi Syndrome [12]; DMD = Duchenne Muscular Dystrophy [12]; CF = Cystic Fibrosis [12]; CrD = Crohn’s Disease [12]; TS = Tuberous Sclerosis [12]; EDS = Ehlers-Danlos Syndrome [12]; FXS = Fragile-X Syndrome [12]; HHT = Hereditary Haemorrhagic Telangiectasia (this work).

References

    1. Dakeishi M, Shioya T, Wada Y, Shindo T, Otaka K, Manabe M, Nozaki J, Inoue S, Koizumi A. Genetic epidemiology of hereditary hemorrhagic telangiectasia in a local community in the northern part of Japan. Hum Mutat. 2002;19:140–148. doi: 10.1002/humu.10026.
    1. Begbie ME, Wallace GM, Shovlin CL. Hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): a view from the 21st century. Postgrad Med J. 2003;79:18–24. doi: 10.1136/pmj.79.927.18.
    1. Abdalla SA, Letarte M. Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. J Med Genet. 2006;43:97–110.
    1. Shovlin CL. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev. 2010;24:203–219. doi: 10.1016/j.blre.2010.07.001.
    1. Cole SG, Begbie ME, Wallace GM, Shovlin CL. A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5. J Med Genet. 2005;42:577–582. doi: 10.1136/jmg.2004.028712.
    1. Bayrak-Toydemir P, Mao R, Lewin S, McDonald J. Hereditary hemorrhagic telangiectasia: an overview of diagnosis and management in the molecular era for clinicians. Genet Med. 2004;6:175–191. doi: 10.1097/01.GIM.0000132689.25644.7C.
    1. Sekarski LA, Spangenberg LA. Hereditary hemorrhagic telangiectasia: children need screening too. Pediatr Nurs. 2011;37:163–168.
    1. Gattorno M, La Regina M, Martini A, Manna R. An update on autoinflammatory diseases. New concepts for new and old diseases. Clin Exp Rheumatol. 2009;27:354–365.
    1. Shook SJ, Pioro EP. Racing against the clock: recognizing, differentiating, diagnosing, and referring the amyotrophic lateral sclerosis patient. Ann Neurol. 2009;65(Suppl 1):s10–s16.
    1. Campos MA, Alazami S, Zhang G, Salathe M, Wanner A, Sandhaus RA, Baier H. Clinical characteristics of subjects with symptoms of alpha1-antitrypsin deficiency older than 60 years. Chest. 2009;135:600–608. doi: 10.1378/chest.08-1129.
    1. Pol K, Jarosz M. Relapsing polychondritis: case report and literature review. Pol Arch Med Wewn. 2009;119:680–683.
    1. A report based on the EurordisCare2 and EurordisCare3 Survey. The voice of 12,000 patients.Experiences and expectations of rare disease patients on diagnosis and care in Europe. [ ].
    1. Lenato GM, Lastella P, Di Giacomo MC, Resta N, Suppressa P, Pasculli G, Sabbà C, Guanti G. DHPLC-based mutation analysis of ENG and ALK-1 genes in HHT Italian population. Hum Mutat. 2006;27:213–214.
    1. Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, Kjeldsen AD, Plauchu H. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome) Am J Med Genet. 2000;6:66–67.
    1. Sabbà C, Pasculli G, Lenato GM, Suppressa P, Lastella P, Memeo M, Dicuonzo F, Guanti G. Hereditary hemorrhagic telangiectasia: clinical features in ENG and ALK1 mutation carriers. J Thromb Haemost. 2007;5:1149–1157. doi: 10.1111/j.1538-7836.2007.02531.x.
    1. R Development Core Team: R. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; ISBN 3- 900051-07-0[ ].
    1. Guttmacher AE, Marchuk DA, White RI. Hereditary hemorrhagic telangiectasia. N Engl J Med. 1995;5:918–924.
    1. Sabbà C. A rare and misdiagnosed bleeding disorder: hereditary hemorrhagic telangiectasia. J Thromb Haemost. 2005;3:2201–2210. doi: 10.1111/j.1538-7836.2005.01345.x.
    1. Faughnan ME, Palda VA, Garcia-Tsao G, Geisthoff UW, McDonald J, Proctor DD, Spears J, Brown DH, Buscarini E, Chesnutt MS, Cottin V, Ganguly A, Gossage JR, Guttmacher AE, Hyland RH, Kennedy SJ, Korzenik J, Mager JJ, Ozanne AP, Piccirillo JF, Picus D, Plauchu H, Porteous ME, Pyeritz RE, Ross DA, Sabba C, Swanson K, Terry P, Wallace MC, Westermann CJ. et al.International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet. 2011;48:73–87. doi: 10.1136/jmg.2009.069013.
    1. Cohen JH, Faughnan ME, Letarte M, Vandezande K, Kennedy SJ, Krahn MD. Cost comparison of genetic and clinical screening in families with hereditary hemorrhagic telangiectasia. Am J Med Genet A. 2005;30:153–160.
    1. Pasculli G, Sallustio G, Sabbà C. The need for an interdisciplinary network of investigations on HHT. Curr Pharm Des. 2006;12:1249–1251. doi: 10.2174/138161206776361327.
    1. Folz BJ, Zoll B, Alfke H, Toussaint A, Maier RF, Werner JA. Manifestations of hereditary hemorrhagic telangiectasia in children and adolescents. Eur Arch Otorhinolaryngol. 2006;263:53–61. doi: 10.1007/s00405-005-0956-8.
    1. Cirulli A, Liso A, D'Ovidio F, Mestice A, Pasculli G, Gallitelli M, Rizzi R, Specchia G, Sabbà C. Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia. Acta Haematol. 2003;110:29–32. doi: 10.1159/000072411.
    1. Sadick H, Riedel F, Naim R, Goessler U, Hörmann K, Hafner M, Lux A. Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica. 2005;90:818–828.
    1. Giordano P, Lenato GM, Pierucci P, Suppressa P, Altomare M, Del Vecchio G, Di Bitonto G, De Mattia D, Guanti G, Sabbà C. Effects of VEGF on phenotypic severity in children with hereditary hemorrhagic telangiectasia. J Pediatr Hematol Oncol. 2009;31:577–582. doi: 10.1097/MPH.0b013e3181a1c104.
    1. Cymerman U, Vera S, Pece-Barbara N, Bourdeau A, White RI, Dunn J, Letarte M. Identification of hereditary hemorrhagic telangiectasia type 1 in newborns by protein expression and mutation analysis of endoglin. Pediatr Res. 2000;47:24–35. doi: 10.1203/00006450-200001000-00008.
    1. Sanz-Rodriguez F, Fernandez-L A, Zarrabeitia R, Perez-Molino A, Ramírez JR, Coto E, Bernabeu C, Botella LM. Mutation analysis in Spanish patients with hereditary hemorrhagic telangiectasia: deficient endoglin up-regulation in activated monocytes. Clin Chem. 2004;50:2003–2011. doi: 10.1373/clinchem.2004.035287.
    1. Ojeda-Fernandez L, Barrios L, Rodriguez-Barbero A, Recio-Poveda L, Bernabeu C, Botella LM. Reduced plasma levels of Ang-2 and sEng as novel biomarkers in hereditary hemorrhagic telangiectasia (HHT) Clin Chim Acta. 2010;20:411494–411499.
    1. Bernhardt BA, Zayac C, Pyeritz RE. Why is genetic screening for autosomal dominant disorders underused in families? The case of hereditary hemorrhagic telangiectasia. Genet Med. 2011;13:812–820. doi: 10.1097/GIM.0b013e31821d2e6d.
    1. Fernandez-Lopez A, Sanz-Rodriguez F, Zarrabeitia R, Perez-Molino A, Morales C, Restrepo CM, Ramirez JR, Coto E, Lenato GM, Bernabeu C, Botella LM. Mutation study of Spanish patients with Hereditary Hemorrhagic Telangiectasia and expression analysis of Endoglin and ALK1. Hum Mutat. 2006;27:295.
    1. McDonald JE, Miller FJ, Hallam SE, Nelson L, Marchuk DA, Ward KJ. Clinical manifestations in a large hereditary hemorrhagic telangiectasia (HHT) type 2 kindred. Am J Med Genet. 2000;93:320–327. doi: 10.1002/1096-8628(20000814)93:4<320::AID-AJMG12>;2-R.
    1. HHT Foundation International: HHT Awareness Video. [ ]
    1. Aron DC. Cushing's syndrome: why is diagnosis so difficult? Rev Endocr Metab Disord. 2010;11:105–116. doi: 10.1007/s11154-010-9127-3.
    1. De P, Evans LM, Scanlon MF, Davies JS. "Osler's phenomenon": misdiagnosing Cushing's syndrome. Postgrad Med J. 2003;79:594–596. doi: 10.1136/pmj.79.936.594.

Source: PubMed

3
Iratkozz fel